DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. It offers Dario Engage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications, and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy and distributors; and through e-stores. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone972-4770-4055
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.17 million
Profitability
Miscellaneous
Employees48
OptionableNot Optionable
DarioHealth (NASDAQ:DRIO) Frequently Asked Questions
What is DarioHealth's stock symbol?
DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."
How were DarioHealth's earnings last quarter?
DarioHealth Corp (NASDAQ:DRIO) issued its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. The business earned $1.88 million during the quarter. DarioHealth had a negative return on equity of 386.47% and a negative net margin of 343.72%. View DarioHealth's Earnings History.
When is DarioHealth's next earnings date?
What is the consensus analysts' recommendation for DarioHealth?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DarioHealth.
Has DarioHealth been receiving favorable news coverage?
News coverage about DRIO stock has been trending somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. DarioHealth earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the near future.
Are investors shorting DarioHealth?
DarioHealth saw a drop in short interest in December. As of December 31st, there was short interest totalling 139,244 shares, a drop of 73.0% from the December 14th total of 516,057 shares. Based on an average trading volume of 135,444 shares, the short-interest ratio is presently 1.0 days. Approximately 0.6% of the shares of the company are short sold. View DarioHealth's Current Options Chain.
Who are some of DarioHealth's key competitors?
Some companies that are related to DarioHealth include Alphatec (ATEC), iCAD (ICAD), Apollo Endosurgery (APEN), Arch Therapeutics (ARTH), Motus GI (MOTS), Invo Bioscience (IVOB), Repro-Med Systems (REPR), CAS Medical Systems (CASM), Pro-Dex (PDEX), Spectral Medical (EDTXF), Titan Medical (TMDI), AIT Therapeutics (AITB), Obalon Therapeutics (OBLN), SANUWAVE Health (SNWV) and Nephros (NEPH).
Who are DarioHealth's key executives?
DarioHealth's management team includes the folowing people:
- Mr. Erez Raphael, CEO & Director (Age 45)
- Mr. Zvi Ben David, CFO, Treasurer & Sec. (Age 57)
- Mr. Dror Bacher, Chief Operating Officer (Age 43)
- Mr. Olivier R. Jarry, Pres & Chief Commercial Officer (Age 57)
- Ms. Joao Mendes-Roter, VP of Marketing
How do I buy shares of DarioHealth?
Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DarioHealth's stock price today?
One share of DRIO stock can currently be purchased for approximately $0.8448.
How big of a company is DarioHealth?
DarioHealth has a market capitalization of $20.49 million and generates $5.17 million in revenue each year. DarioHealth employs 48 workers across the globe.
What is DarioHealth's official website?
How can I contact DarioHealth?
DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at 972-4770-4055 or via email at [email protected]
MarketBeat Community Rating for DarioHealth (NASDAQ DRIO)
MarketBeat's community ratings are surveys of what our community members think about DarioHealth and other stocks. Vote "Outperform" if you believe DRIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
